Dr. Mark Stibich, Co-Founder of Xenex Germ-Zapping Robots, Honored as Fellow of Infectious Diseases Society of America

September 10, 2018 — Xenex Disinfection Services, the manufacturer of LightStrike™ Germ-Zapping Robots™, today announced that co-founder and Chief Scientific Officer Mark Stibich, Ph.D., who serves as a Visiting Scientist at the University of Texas MD Anderson Cancer Center, has been recognized as a Fellow of the Infectious Diseases Society of America (IDSA), the nation’s leading infectious diseases professional society.

Nearly 300 people die in the U.S. every day from an infection they acquired in a healthcare facility and the death toll can be even higher internationally. Recognizing the growing threat of antibiotic resistance and superbugs, Dr.Stibich co-founded Xenex with the mission to save lives and reduce suffering by destroying the deadly microorganisms that cause healthcare associated infections (HAIs). Xenex LightStrike robots use pulsed xenon to create intense ultraviolet (UV) light that quickly destroys infectious germs. Today, Dr. Stibich’s robots are used in more than 400 healthcare facilities to disinfect rooms and most importantly, hospitals using Xenex devices have published outcome studies in peer-reviewed journals showing 50{a7dbd90b9ffe087840aba08710c78edd3b62ca0d1e957cc3862d95b1204bafc3}-100{a7dbd90b9ffe087840aba08710c78edd3b62ca0d1e957cc3862d95b1204bafc3} reductions in Clostridium difficile (C.diff), Methicillin-resistant Staphylococcus aureus (MRSA) and Surgical Site Infection rates when those facilities used Xenex robots to disinfect rooms.

At Xenex, Dr. Stibich focuses his efforts on scientific research and development, new technology and protocol design. He is an inventor on multiple patents and has authored numerous scientific papers about the efficacy of pulsed xenon UV technology. Originally from Dayton, Ohio, Dr. Stibich is a graduate of Yale University and the Johns Hopkins University School of Public Health, where he earned MHS and Ph.D. degrees.

“Mark is a brilliant epidemiologist who has dedicated his career to serving and helping others. His selfless dedication to finding a solution for a global epidemic – hospital acquired infections — is inspiring to all of us who work alongside him,” said Morris Miller, CEO of Xenex. “Being recognized by IDSA for his achievements and stopping these preventable infections is a high honor and well deserved.”

Fellowship in IDSA honors the distinguished physicians and scientists from the United States and around the world who have achieved professional excellence and provided significant service to the profession. Applicants for IDSA Fellowship must be nominated by their peers and meet specified criteria that may include continuing identification with the field of infectious diseases national or regional recognition, and publication of their scholarly work.

About Xenex Disinfection Services

Xenex’s patented Full Spectrum™ pulsed xenon UV room disinfection system is used for the advanced disinfection of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. Xenex’s mission is to save lives and reduce suffering by destroying the deadly microorganisms that cause healthcare associated infections (HAIs). The company is backed by well-known investors that include EW Healthcare Partners, Piper Jaffray Merchant Services, Malin Corporation, Battery Ventures, Tectonic Ventures, Targeted Technology Fund II and RK Ventures. For more information, visit Xenex.com.

Credit Melinda Hart